Approved for the treatment of thyroid eye disease (TED) in 2020, teprotumumab has been shown to reduce symptomatic diplopia by nearly 90% in clinical trials. In her presentation at the AAO 2023 symposium on "Adult Strabismus for the Comprehensive Ophthalmologist," Dr. Natalie Kerr notes that the availability of teprotumumab means that fewer patients with TED will need strabismus surgery, and those who do present for surgery will have been less likely to have needed orbital decompression. However, one key question remains: Will teprotumumab change how patients with TED respond to strabismus surgery?